Targeted, Non-Systemic Therapies for Gastrointestinal Diseases
THE SCIENCE
First Wave BioPharma’s product portfolio is built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties.
LEARN MOREPIPELINE
First Wave BioPharma’s GI-disease focused programs span multiple clinical indications ranging from nutritional disorders to diseases brought on by immune malfunction. Disease targets include patient populations with digestive disorders, such as exocrine pancreatic insufficiency in cystic fibrosis patients, and inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease.
IN THE NEWS
|
May 17, 2022
First Wave BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Investment Conference
|
|
Apr 29, 2022
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
|
|
Apr 27, 2022
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
|
